# A Preliminary Integrated Metabolomics Analysis Identifies Retrograde Endocannabinoid Signaling Shift in Severe OSA Patients

**Authors:** Li Han, Jinjin Liu, Juan Xu, Xiaoyan Li, Rui Chen

PMC · DOI: 10.1007/s11325-025-03425-w · Sleep & Breathing = Schlaf & Atmung · 2025-07-31

## TL;DR

This study finds that severe obstructive sleep apnea disrupts key metabolic pathways, including retrograde endocannabinoid signaling, which could explain its broader health effects.

## Contribution

The novel finding is the identification of retrograde endocannabinoid signaling pathway shifts in severe OSA patients through integrated metabolomics analysis.

## Key findings

- Severe OSA patients showed significant alterations in 59 GC–MS and 27 LC–MS metabolites.
- Retrograde endocannabinoid signaling was the only common pathway altered in both GC–MS and LC–MS data.
- Sleep fragmentation was linked to increased ROS production in severe OSA patients.

## Abstract

The systemic influence of obstructive sleep apnea(OSA), particularly in those with severe OSA (sOSA), has frequently been disregarded. An investigation was conducted to examine the variations of reactive oxygen species (ROS) and metabolomic drifts, as well as their interrelations, in adult OSA patients.

A total of 22 male patients were enrolled after undergoing polysomnography (PSG), and blood samples were obtained. Following the measurement of ROS levels in polymorphonuclear neutrophils (PMNs), plasma samples were combined and analyzed using both Gas Chromatography-Mass Spectrometry (GC–MS) and Liquid Chromatography-Mass Spectrometry (LC–MS).

Patients with sOSA had a higher body mass index (BMI) (p = 0.005) and more negative PSG measures compared to those with mild/moderate OSA (mOSA). Although there was no remarkable difference in neutrophil ROS between the mOSA and sOSA group, further analysis indicated sleep fragmentation was associated with ROS production(p = 0.043 for N3%, p < 0.01 for Arousal Index). Integrated metabolomics analysis revealed significant alterations in 59 metabolites from GC–MS and 27 metabolites from LC–MS in sOSA patients. These substantial changes perturbed various pathways, including the FoxO signaling pathway and its upstream PI3K-Akt signaling pathway, and so on. Notably, the retrograde endocannabinoid signaling pathway was the sole common pathway identified in both GC–MS and LC–MS data.

This study sheds light on the systemic impact of OSA, particularly in severe cases, by uncovering extensive disturbance of metabolic pathways. The identification of retrograde endocannabinoid signaling shifts in severe OSA adults highlights its potential impact in the sleep disorder and its broader repercussions in the body.

## Linked entities

- **Diseases:** obstructive sleep apnea (MONDO:0007147)

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MGLL (monoglyceride lipase) [NCBI Gene 11343] {aka HU-K5, HUK5, MAGL, MGL}, CNR1 (cannabinoid receptor 1) [NCBI Gene 1268] {aka CANN6, CB-R, CB1, CB1A, CB1K5, CB1R}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, SST (somatostatin) [NCBI Gene 6750] {aka SMST, SST1}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CYTH3 (cytohesin 3) [NCBI Gene 9265] {aka ARNO3, GRP1, PSCD3, cytohesin-3}, IGFBP1 (insulin like growth factor binding protein 1) [NCBI Gene 3484] {aka AFBP, IBP1, IGF-BP25, PP12, hIGFBP-1}, VIP (vasoactive intestinal peptide) [NCBI Gene 7432] {aka PHM27}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, RORC (RAR related orphan receptor C) [NCBI Gene 6097] {aka IMD42, NR1F3, RORG, RZR-GAMMA, RZRG, TOR}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** apnea-hyponea (MESH:D001049), Sleep Fragmentation (MESH:D012892), weight loss (MESH:D015431), OSA (MESH:D020181), cardiovascular disease (MESH:D002318), anxiety (MESH:D001007), sOSA (MESH:D045169), depression (MESH:D003866), OSA (MESH:C535586), metabolic syndrome (MESH:D024821), insulin resistance (MESH:D007333), stroke (MESH:D020521), ischaemic heart disease (MESH:D006331), inflammation (MESH:D007249), cancer (MESH:D009369), metabolic abnormalities (MESH:D008659), infections (MESH:D007239), COPD (MESH:D029424), sleep disorder (MESH:D012893), autoimmune diseases (MESH:D001327), reperfusion injury (MESH:D015427), obese (MESH:D009765), hypertension (MESH:D006973), IH (MESH:D000860), myocardial damage (MESH:D009202), cognitive deficits (MESH:D003072), diabetes (MESH:D003920), ischemia (MESH:D007511), heart failure (MESH:D006333), neurodegeneration (MESH:D019636)
- **Chemicals:** arachidonic acids (MESH:D001095), stearic acid (MESH:C031183), erucic acid (MESH:C049811), catecholamines (MESH:D002395), TG (MESH:D014280), helium (MESH:D006371), pyrimidine (MESH:C030986), behenic acid (MESH:C007547), lipid (MESH:D008055), alcohol (MESH:D000438), lignoceric acid (MESH:C010210), ROS (MESH:D017382), Endocannabinoid (MESH:D063388), palmitic acid (MESH:D019308), fatty acids (MESH:D005227), nitrogen (MESH:D009584), MC (MESH:C061001), eicosapentaenoic acid (MESH:D015118), amino acid (MESH:D000596), deoxy sugars (MESH:D003837), GC (MESH:C057580), TCA (MESH:D014238), glycosides (MESH:D006027), nucleosides (MESH:D009705), arachidic acid (MESH:C094477), phosphates (MESH:D010710), cannabinoid (MESH:D002186), heptadecanoic acid (MESH:C013102), H2S (MESH:D006862), uric acid (MESH:D014527), anandamide (MESH:C078814), bicarbonate (MESH:D001639), unsaturated fatty acid (MESH:D005231), oxygen (MESH:D010100), cholesterol (MESH:D002784), glucose (MESH:D005947), acetonitrile (MESH:C032159), Arachidonic acid (MESH:D016718), HCY (MESH:D006710), methanol (MESH:D000432), phospholipids (MESH:D010743), AEA (-), 2-AG (MESH:C094503), choline (MESH:D002794)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12313796/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12313796/full.md

---
Source: https://tomesphere.com/paper/PMC12313796